Verve Therapeutics, Inc. (NASDAQ:VERV) Insider Joan Nickerson Sells 2,777 Shares

Verve Therapeutics, Inc. (NASDAQ:VERV) insider Joan Nickerson sold 2,777 shares of Verve Therapeutics stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a total transaction of $11,524.55. Following the transaction, the insider now owns 17,420 shares of the company’s stock, valued at $72,293. This represents a 13.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Verve Therapeutics Trading Down 1.5 %

Shares of VERV stock traded down $0.06 during trading on Thursday, hitting $3.85. The company’s stock had a trading volume of 2,477,105 shares, compared to its average volume of 1,431,392. The company has a market cap of $341.86 million, a PE ratio of -1.57 and a beta of 1.77. The business has a fifty day moving average of $6.78 and a 200-day moving average of $6.05. Verve Therapeutics, Inc. has a 52 week low of $3.69 and a 52 week high of $9.31.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business had revenue of $13.08 million for the quarter, compared to analysts’ expectations of $3.94 million. As a group, research analysts predict that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Institutional Trading of Verve Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. boosted its stake in Verve Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock valued at $101,000 after acquiring an additional 1,676 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Verve Therapeutics by 1.9% in the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock worth $627,000 after purchasing an additional 2,093 shares during the period. Arizona State Retirement System raised its holdings in shares of Verve Therapeutics by 15.8% in the 4th quarter. Arizona State Retirement System now owns 19,593 shares of the company’s stock worth $111,000 after purchasing an additional 2,669 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Verve Therapeutics by 5.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company’s stock valued at $313,000 after purchasing an additional 2,742 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Verve Therapeutics by 5.7% during the fourth quarter. Invesco Ltd. now owns 57,140 shares of the company’s stock valued at $322,000 after purchasing an additional 3,080 shares during the period. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Analyst Ratings Changes

VERV has been the topic of several recent research reports. Guggenheim reaffirmed a “buy” rating on shares of Verve Therapeutics in a research report on Tuesday, March 25th. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Royal Bank of Canada decreased their price target on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verve Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.50.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.